drugset / Trial / NCT00378560

V501 Efficacy Study in Women Aged 18 to 26 (V501-027)

NCT00378560

Phase 2 Completed 1021 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindPrevention

Summary

A study to evaluate the efficacy, immunogenicity, safety and tolerability of V501 in adult women

Timeline

Start
2006-06-12
Primary completion
2009-09-16
Completion
2009-09-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Gardasil Vaccine 0.5 ml Other